Critical Path Institute’s John-Michael Sauer, Ph.D. presents information on fluid-based biomarkers and how they can be applied to help advance polycystic kidney disease drug development for patients across the globe. C-Path’s Polycystic Kidney Disease Outcomes Consortium investigates tools and promotes research that will lead to the development and regulatory approval of new therapies for PKD.
Watch now: https://youtu.be/4OXEMYXpOvI
